With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
August 18, 2017. The PI3K/AKT pathway is a popular target in cancer research since its activation is frequently a main driver of proliferation. Especially in triple negative breast cancer (TNBC), a subtype which, unlike the others, has not seen many recent advancements in treatment options. The LOTUS trial now out in Lancet Oncology puts all that theoretical science to a real-world test. It randomized women with previously untreated locally-advanced or metastatic TNBC to paclitaxel +/- ipatasertib. Ipatasertib is a small molecule that competes with ATP for binding sites on Akt, which is a middle-man for PI3K activation of the mTOR pathway. While ipatasertib caused a lot of extra diarrhea and neutropenia, it improved median progression free survival from 4.9 to 6.2 months. This represents a two-fold victory: clinical control of a difficult-to-control pathway...and a difficult-to-control disease. But don’t eat from the lotus tree just yet. We still have a long way to go in achieving a tolerable treatment with substantial survival benefits for our TNBC patients.